rhDNase as an example of recurrent event analysisTHERNEAU, T. M; HAMILTON, S. A.Statistics in medicine. 1997, Vol 16, Num 18, pp 2029-2047, issn 0277-6715Article

Optimal two-stage screening designs for survival comparisonsSCHAID, D. J; WIEAND, S; THERNEAU, T. M et al.Biometrika. 1990, Vol 77, Num 3, pp 507-513, issn 0006-3444Article

Optimal designs for a grouped sequential binomial trialTHERNEAU, T. M; WIEAND, H. S; CHANG, M et al.Biometrics. 1990, Vol 46, Num 3, pp 771-781, issn 0006-341XArticle

Prognosis of histological cirrhosis in type 1 autoimmune hepatitisROBERTS, S. K; THERNEAU, T. M; CZAJA, A. J et al.Gastroenterology (New York, NY. 1943). 1996, Vol 110, Num 3, pp 848-857, issn 0016-5085Article

Martingale-based residuals for survival modelsTHERNEAU, T. M; GRAMBSCH, P. M; FLEMING, T. R et al.Biometrika. 1990, Vol 77, Num 1, pp 147-160, issn 0006-3444Article

Long-term trends in hip fracture prevalence : The influence of hip fracture incidence and survivalMELTON, L. J; THERNEAU, T. M; LARSON, D. R et al.Osteoporosis international. 1998, Vol 8, Num 1, pp 68-74, issn 0937-941XArticle

Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosisANGULO, P; BATTS, K. P; THERNEAU, T. M et al.Hepatology (Baltimore, Md.). 1999, Vol 29, Num 3, pp 644-647, issn 0270-9139Article

Clonal circulating cells are common in plasma cell proliferative disorders : A comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myelomaBILLADEAU, D; VAN NESS, B; KIMLINGER, T et al.Blood. 1996, Vol 88, Num 1, pp 289-296, issn 0006-4971Article

Inhibition of fluorouracil-induced stomatitis by oral cryotherapyMAHOOD, D. J; DOSE, A. M; FINCK, G. K et al.Journal of clinical oncology. 1991, Vol 9, Num 3, pp 449-452, issn 0732-183XArticle

Rapid S-phase determination of non-Hodgkin's lymphomas with the use of an immunofluorescence bromodeoxyuridine labeling index procedureWITZIG, T. E; GONCHOROFF, N. J; GREIPP, P. R et al.American journal of clinical pathology. 1989, Vol 91, Num 3, pp 298-301, issn 0002-9173Article

Normalization of two-channel microarray experiments: a semiparametric approachECKEL, J. E; GENNINGS, C; THERNEAU, T. M et al.Bioinformatics (Oxford. Print). 2005, Vol 21, Num 7, pp 1078-1083, issn 1367-4803, 6 p.Article

A revised natural history model for primary sclerosing cholangitisKIM, W. R; THERNEAU, T. M; WIESNER, R. H et al.Mayo Clinic proceedings. 2000, Vol 75, Num 7, pp 688-694, issn 0025-6196Article

Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis : a randomized trialANGULO, P; DICKSON, E. R; THERNEAU, T. M et al.Journal of hepatology. 1999, Vol 30, Num 5, pp 830-835, issn 0168-8278Article

Fifty-year follow-up of cancer incidence in a historical cohort of Minnesota Breast Cancer FamiliesSELLERS, T. A; KING, R. A; THERNEAU, T. M et al.Cancer epidemiology, biomarkers & prevention. 1999, Vol 8, Num 12, pp 1051-1057, issn 1055-9965Article

Increased risk of chronic liver failure in adults with heterozygous α₁-Antitrypsin deficiencyGRAZIADEI, I. W; JOSEPH, J. J; WIESNER, R. H et al.Hepatology (Baltimore, Md.). 1998, Vol 28, Num 4, pp 1058-1063, issn 0270-9139Article

Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis CKIM, W. R; POTERUCHA, J. J; HERMANS, J. E et al.Annals of internal medicine. 1997, Vol 127, Num 10, pp 866-874, issn 0003-4819Article

Time course of histological progression in primary biliary cirrhosisLOCKE, G. R; THERNEAU, T. M; LUDWIG, J et al.Hepatology (Baltimore, Md.). 1996, Vol 23, Num 1, pp 52-56, issn 0270-9139Conference Paper

Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometryWINKLER, H. Z; RAINWATER, L. M; MYERS, R. P et al.Mayo Clinic proceedings. 1988, Vol 63, Num 2, pp 103-112, issn 0025-6196Article

Designs for group sequential phase II clinical trialsCHANG, M. N; THERNEAU, T. M; WIEAND, H. S et al.Biometrics. 1987, Vol 43, Num 4, pp 865-874, issn 0006-341XArticle

Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myelomaRAJKUMAR, S. V; FONSECA, R; DEWALD, G. W et al.Cancer genetics and cytogenetics. 1999, Vol 113, Num 1, pp 73-77, issn 0165-4608Article

Evaluation of consultation-based rehabilitation for hospitalized cancer patients with functional impairmentSABERS, S. R; KOKAL, J. E; GIRARDI, J. C et al.Mayo Clinic proceedings. 1999, Vol 74, Num 9, pp 855-861, issn 0025-6196Article

Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myelomaRAJKUMAR, S. V; FONSECA, R; LACY, M. Q et al.Journal of clinical oncology. 1999, Vol 17, Num 5, pp 1551-1557, issn 0732-183XArticle

A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicineKYLE, R. A; GERTZ, M. A; GREIPP, P. R et al.The New England journal of medicine. 1997, Vol 336, Num 17, pp 1202-1207, issn 0028-4793Article

Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosisLINDOR, K. D; THERNEAU, T. M; JORGENSEN, R. A et al.Gastroenterology (New York, NY. 1943). 1996, Vol 110, Num 5, pp 1515-1518, issn 0016-5085Article

Phase II evaluation of menogaril in patients with advanced hypernephromaLONG, H. J; HAUGE, M. D; THERNEAU, T. M et al.Investigational new drugs. 1991, Vol 9, Num 3, pp 261-262, issn 0167-6997, 2 p.Article